Pulmonx (LUNG) Competitors

$1.34 +0.01 (+0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$1.34 0.00 (0.00%)

As of 04:10 PM Eastern

LUNG vs. STEX, ELMD, CVRX, INFU, and LUCD

Should you buy Pulmonx stock or one of its competitors? MarketBeat compares Pulmonx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pulmonx include Biosig Technologies (STEX), Electromed (ELMD), CVRx (CVRX), InfuSystem (INFU), and Lucid Diagnostics (LUCD). These companies are all part of the "medical equipment" industry.

How does Pulmonx compare to Biosig Technologies?

Biosig Technologies (NASDAQ:STEX) and Pulmonx (NASDAQ:LUNG) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Biosig Technologies has a net margin of 0.00% compared to Pulmonx's net margin of -60.09%. Pulmonx's return on equity of -92.94% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-1,476.78%	-428.30%
Pulmonx	-60.09%	-92.94%	-39.80%

Pulmonx has higher revenue and earnings than Biosig Technologies. Pulmonx is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	4,329.25	-$462.77M	-$9.58	N/A
Pulmonx	$90.50M	0.63	-$54M	-$1.30	N/A

In the previous week, Biosig Technologies had 3 more articles in the media than Pulmonx. MarketBeat recorded 4 mentions for Biosig Technologies and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.87 beat Biosig Technologies' score of 0.81 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Overall Sentiment
Biosig Technologies	Positive
Pulmonx	Very Positive

Biosig Technologies has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, Pulmonx has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

Biosig Technologies presently has a consensus price target of $9.00, indicating a potential upside of 841.42%. Pulmonx has a consensus price target of $5.38, indicating a potential upside of 301.39%. Given Biosig Technologies' higher possible upside, equities research analysts plainly believe Biosig Technologies is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pulmonx	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by insiders. Comparatively, 6.8% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Pulmonx beats Biosig Technologies on 9 of the 16 factors compared between the two stocks.

How does Pulmonx compare to Electromed?

Electromed (NYSE:ELMD) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Electromed presently has a consensus price target of $37.50, indicating a potential upside of 2.74%. Pulmonx has a consensus price target of $5.38, indicating a potential upside of 301.39%. Given Pulmonx's higher probable upside, analysts plainly believe Pulmonx is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Pulmonx	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

40.8% of Electromed shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 10.5% of Electromed shares are owned by insiders. Comparatively, 6.8% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Electromed has a net margin of 11.34% compared to Pulmonx's net margin of -60.09%. Electromed's return on equity of 15.71% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Pulmonx	-60.09%	-92.94%	-39.80%

Electromed has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market.

Electromed has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$68.86M	4.39	$5.15M	$1.03	35.44
Pulmonx	$90.50M	0.63	-$54M	-$1.30	N/A

In the previous week, Electromed had 4 more articles in the media than Pulmonx. MarketBeat recorded 5 mentions for Electromed and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.87 beat Electromed's score of 0.45 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Overall Sentiment
Electromed	Neutral
Pulmonx	Very Positive

Summary

Electromed beats Pulmonx on 11 of the 16 factors compared between the two stocks.

How does Pulmonx compare to CVRx?

Pulmonx (NASDAQ:LUNG) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

CVRx has lower revenue, but higher earnings than Pulmonx. CVRx is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.63	-$54M	-$1.30	N/A
CVRx	$56.65M	2.69	-$53.31M	-$2.02	N/A

In the previous week, CVRx had 14 more articles in the media than Pulmonx. MarketBeat recorded 15 mentions for CVRx and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.87 beat CVRx's score of 0.43 indicating that Pulmonx is being referred to more favorably in the media.

Company	Overall Sentiment
Pulmonx	Very Positive
CVRx	Neutral

Pulmonx presently has a consensus target price of $5.38, suggesting a potential upside of 301.39%. CVRx has a consensus target price of $11.50, suggesting a potential upside of 100.35%. Given Pulmonx's higher possible upside, research analysts clearly believe Pulmonx is more favorable than CVRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00

Pulmonx has a net margin of -60.09% compared to CVRx's net margin of -89.14%. Pulmonx's return on equity of -92.94% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
CVRx	-89.14%	-120.76%	-48.38%

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 75.3% of CVRx shares are held by institutional investors. 6.8% of Pulmonx shares are held by company insiders. Comparatively, 13.9% of CVRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Pulmonx has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market. Comparatively, CVRx has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Summary

Pulmonx beats CVRx on 10 of the 17 factors compared between the two stocks.

How does Pulmonx compare to InfuSystem?

InfuSystem (NYSE:INFU) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

In the previous week, InfuSystem had 11 more articles in the media than Pulmonx. MarketBeat recorded 12 mentions for InfuSystem and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.87 beat InfuSystem's score of 0.75 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Overall Sentiment
InfuSystem	Positive
Pulmonx	Very Positive

71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by insiders. Comparatively, 6.8% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

InfuSystem has a net margin of 1.12% compared to Pulmonx's net margin of -60.09%. InfuSystem's return on equity of 2.78% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Pulmonx	-60.09%	-92.94%	-39.80%

InfuSystem currently has a consensus target price of $15.00, suggesting a potential upside of 74.22%. Pulmonx has a consensus target price of $5.38, suggesting a potential upside of 301.39%. Given Pulmonx's higher probable upside, analysts clearly believe Pulmonx is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pulmonx	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

InfuSystem has higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40M	1.22	$870K	$0.38	22.66
Pulmonx	$90.50M	0.63	-$54M	-$1.30	N/A

InfuSystem has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Pulmonx has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

Summary

InfuSystem beats Pulmonx on 12 of the 16 factors compared between the two stocks.

How does Pulmonx compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Pulmonx has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	42.28	-$58.01M	-$0.96	N/A
Pulmonx	$90.50M	0.63	-$54M	-$1.30	N/A

Pulmonx has a net margin of -60.09% compared to Lucid Diagnostics' net margin of -1,426.27%. Lucid Diagnostics' return on equity of 0.00% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-1,426.27%	N/A	-95.51%
Pulmonx	-60.09%	-92.94%	-39.80%

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 6.8% of Lucid Diagnostics shares are owned by insiders. Comparatively, 6.8% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lucid Diagnostics currently has a consensus target price of $4.13, suggesting a potential upside of 304.41%. Pulmonx has a consensus target price of $5.38, suggesting a potential upside of 301.39%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, research analysts clearly believe Lucid Diagnostics is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Pulmonx	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Lucid Diagnostics had 8 more articles in the media than Pulmonx. MarketBeat recorded 9 mentions for Lucid Diagnostics and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.87 beat Lucid Diagnostics' score of -0.33 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Overall Sentiment
Lucid Diagnostics	Neutral
Pulmonx	Very Positive

Lucid Diagnostics has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Pulmonx has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market.

Summary

Lucid Diagnostics and Pulmonx tied by winning 7 of the 14 factors compared between the two stocks.

Get Pulmonx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUNG vs. The Competition

Export

Metric	Pulmonx	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$56.17M	$1.41B	$6.34B	$12.38B
Dividend Yield	N/A	N/A	2.80%	5.35%
P/E Ratio	-1.03	64.07	20.90	25.61
Price / Sales	0.63	6.19	549.93	78.79
Price / Cash	N/A	22.91	43.26	56.33
Price / Book	1.24	5.23	9.93	6.96
Net Income	-$54M	-$54.76M	$3.55B	$333.52M
7 Day Performance	5.51%	-3.77%	-0.33%	0.45%
1 Month Performance	-5.63%	4.64%	1.34%	4.06%
1 Year Performance	-58.90%	-4.63%	41.10%	36.24%

Pulmonx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUNG Pulmonx	2.6307 of 5 stars	$1.34 +0.8%	$5.38 +301.4%	-59.9%	$56.17M	$90.50M	N/A	250	Positive News
STEX Biosig Technologies	2.273 of 5 stars	$1.02 -14.0%	$9.00 +786.7%	N/A	$213.75M	$40K	N/A	50	Earnings Report
ELMD Electromed	0.7275 of 5 stars	$25.56 -0.2%	$36.67 +43.5%	+49.1%	$211.51M	$68.86M	34.08	160	News Coverage Analyst Forecast Gap Up
CVRX CVRx	3.373 of 5 stars	$7.80 -2.1%	$10.50 +34.6%	-4.0%	$210.65M	$56.65M	N/A	160	News Coverage Earnings Report
INFU InfuSystem	4.5205 of 5 stars	$10.39 +0.2%	$15.00 +44.4%	+42.8%	$209.82M	$143.44M	173.20	410	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUNG) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulmonx (LUNG) Competitors

LUNG vs. STEX, ELMD, CVRX, INFU, and LUCD

How does Pulmonx compare to Biosig Technologies?

Summary

How does Pulmonx compare to Electromed?

Summary

How does Pulmonx compare to CVRx?

Summary

How does Pulmonx compare to InfuSystem?

Summary

How does Pulmonx compare to Lucid Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG vs. The Competition

Pulmonx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulmonx (LUNG) Competitors

LUNG vs. STEX, ELMD, CVRX, INFU, and LUCD

How does Pulmonx compare to Biosig Technologies?

Is STEX or LUNG more profitable?

Which has stronger valuation and earnings, STEX or LUNG?

Does the media prefer STEX or LUNG?

Which has more volatility and risk, STEX or LUNG?

Do analysts prefer STEX or LUNG?

Do insiders and institutionals have more ownership in STEX or LUNG?

Summary

How does Pulmonx compare to Electromed?

Do analysts prefer ELMD or LUNG?

Do institutionals and insiders have more ownership in ELMD or LUNG?

Is ELMD or LUNG more profitable?

Which has more risk and volatility, ELMD or LUNG?

Which has higher valuation & earnings, ELMD or LUNG?

Does the media prefer ELMD or LUNG?

Summary

How does Pulmonx compare to CVRx?

Which has preferable earnings and valuation, LUNG or CVRX?

Does the media favor LUNG or CVRX?

Do analysts rate LUNG or CVRX?

Is LUNG or CVRX more profitable?

Do insiders & institutionals have more ownership in LUNG or CVRX?

Which has more volatility and risk, LUNG or CVRX?

Summary

How does Pulmonx compare to InfuSystem?

Does the media refer more to INFU or LUNG?

Do institutionals & insiders hold more shares of INFU or LUNG?

Is INFU or LUNG more profitable?

Do analysts prefer INFU or LUNG?

Which has higher earnings and valuation, INFU or LUNG?

Which has more risk & volatility, INFU or LUNG?

Summary

How does Pulmonx compare to Lucid Diagnostics?

Which has stronger valuation & earnings, LUCD or LUNG?

Is LUCD or LUNG more profitable?

Do insiders and institutionals hold more shares of LUCD or LUNG?

Do analysts prefer LUCD or LUNG?

Does the media prefer LUCD or LUNG?

Which has more volatility and risk, LUCD or LUNG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG vs. The Competition

Pulmonx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools